Point72 Asia (Singapore) Pte. Ltd. Pacira Bio Sciences, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $379 Billion
- Q4 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 5,450 shares of PCRX stock, worth $137,122. This represents 0.03% of its overall portfolio holdings.
Number of Shares
5,450Holding current value
$137,122% of portfolio
0.03%Shares
2 transactions
Others Institutions Holding PCRX
# of Institutions
260Shares Held
49.8MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$201 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$132 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$82.1 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$56.8 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$50.1 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.15B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...